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outcomes, 1 duplicate publication, 3 review articles, and 4 articles that did not
differentiate nocturia from other urinary symptoms. A total of 14 studies were
included in the analysis. Six major constructs of sleep were used. Five validated
measurement tools were utilized by eight different studies. Nocturia was associ-
ated with an increase in sleep disturbance, increase in napping, increase in insom-
nia risk, and overall decrease of sleep quality, but the lack of a consistent outcome
measures prevented quantitative synthesis.CONCLUSIONS:Nocturia is associated
with an increase risk of falls and fractures. It is also associated with a decrease in
sleep quality and increase in sleep disturbance.
URINARY/KIDNEY DISORDERS – Cost Studies
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OBJECTIVES: Widely disparate definitions of renal injury or failure have histori-
cally been used in epidemiologic studies, not always in accordance with the RIFLE
(risk, injury and failure) criteria. This has resulted in awide range of incidence rates
in the published literature. The clinical epidemiology analysis of AKI estimates an
incidence rate of 200/100,000 in the all-age population and 25/100,000 in the all-age
population receiving renal replacement therapy. Our objective was to estimate the
prevalence and examine the related health care burden of acute kidney injury
(AKI). METHODS: Patients diagnosed with AKI in 2009 were identified in the Op-
tumInsight Impact database. Projections for the US Population were based on the
age-adjusted prevalence per 100,000 for patients with at least one paid claim that
specified an AKI diagnosis during 2009. A sample matched for age and gender was
created to compare health care costs. RESULTS: Based on the age-adjusted preva-
lence in the OptumInsight Impact database of 480 per 100,000 patients in 2009, the
projection to the US population was 1,473,232 individuals with AKI; 40% of these
patients were exposed to contrast media; nearly 30% had cardiovascular (CV) sur-
gery, and over 20% of patients also hadmajor digestive surgery. Mean annual costs
in 2009 were $64,594, including outpatient, inpatient, ER, and pharmacy
(N116,994 AKI patients). This included costs specifically related to AKI ($19,115).
Among AKI patients that had dialysis, the mean annual procedure-related costs
($44,065, N10,879) were comparable to all patients receiving dialysis ($46,884).
However, AKI patients typically demonstrated substantially higher procedure-re-
lated costs for major digestive surgery, major CV surgery, and contrast media ex-
posure, in comparison to all patients undergoing each of these procedures.
CONCLUSIONS: AKI prevalence was higher than expected, and was associated
with a high economic burden as demonstrated by procedure-related costs. To un-
derstand the pattern of risk, longitudinal examination is needed.
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OBJECTIVES: The increasing number of patients developing end-stage renal dis-
ease (ESRD) is driving up the costs of care dramatically. Effective January 1, 2011,
Medicare implemented a bundled prospective payment system (PPS). This study
investigates the five-year budget impact on Medicare under the new PPS of chang-
ing the distribution of patients undergoing peritoneal dialysis (PD) and in-center
hemodialysis (ICHD). METHODS: We constructed an Excel®-based budget impact
model to assess dialysis-associatedMedicare costswhen shifting patients between
PD and ICHD. The model incorporates the current modality distribution and ac-
counts for Medicare dialysis payments (including start-up costs), oral drug costs,
and the costs and probabilities of adverse events including access failure, access
infection, pneumonia, and cardiovascular events. Data from the United States Re-
nal Data System (USRDS) were used to estimate the US Medicare dialysis patient
population for the next five years. The baseline scenario assumed a stable distri-
bution of PD (8.0%) and ICHD (90.5%) over five years; the remaining 1.5% is assumed
to practice home hemodialysis. Alternative scenarios assumed the prevalence of
PD decreased by 0.5% or increased by 0.5% or 1% each year for five years, with
commensurate changes in ICHD. Differences among scenarios were evaluated in
terms of costs to Medicare and numbers of adverse events. RESULTS: Under the
bundled PPS, an increase in the prevalent PD population from 8.0% in 2012 to 10%
or 12% in 2016 is predicted to result in five-year cumulative savings for Medicare of
$37 million and $74 million, respectively. If the prevalent PD population were to
decrease from 8.0% in 2012 to 6.0% by 2016, the total Medicare payment for dialysis
patients would increase by $37 million over 5 years CONCLUSIONS: Under Medi-
care bundled PPS, shifting patients from ICHD to PD could help Medicare reduce
dialysis-associated costs.
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OBJECTIVES: To compare retrospective data of erythropoiesis-stimulating agent
(ESA) dosing patterns and costs among hospital outpatients with dialysis chronic
kidney disease (CKD) not on dialysis. METHODS: Electronic records from the Pre-
mier hospital database (2006Q1-2011Q1) were used to identify outpatients that had
a diagnosis for CKD and received epoetin alfa (EPO) or darbepoetin alfa (DARB).
Exclusion criteria were: age 18 years, receipt of renal dialysis, a diagnosis of
cancer or myelodysplastic syndrome, receipt of chemotherapy, or receipt of both
ESAs. The observation period consisted of the outpatient continuous ESA episode,
defined as the period from first to last outpatient visit with ESA use without a gap
of more than one calendar month between ESA visits. The ESA dose ratio (Units
EPO: mcg DARB) was calculated using themean cumulative dose of EPO and DARB.
Treatment costs for both ESA groups were determined using cumulative dose and
published July 2011 wholesale acquisition costs. RESULTS: A total of 9770 outpa-
tient ESA episodes (EPO: 5398; DARB: 4,72) were identified. EPO and DARB groups
had a similar mean age (73.1 vs. 73.5 years, respectively; P0.104) and similar
proportion of females (59.4% vs. 59.0%, respectively; P0.663). EPO group had a
longer duration of outpatient episode (3.8months vs. 3.4months, P0.001) than the
DARB group. Themean cumulative dose was EPO 174,010 Units and DARB 622mcg,
which resulted in a dose ratio (Units EPO:mcg DARB) of 280:1. Correspondingmean
ESA treatment costs were higher for DARB than for EPO (EPO: $2,819 vs. DARB:
$3,484, P0.001). CONCLUSIONS: In this analysis of non-dialysis CKD hospital out-
patient records, a dose ratio (Units EPO: mcg DARB) of 280:1 was observed. Mean
ESA treatment costs were found to be approximately 24% higher for the DARB
group as compared to the EPO group.
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OBJECTIVES: To compare retrospective data of erythropoiesis-stimulating agent
(ESA) dosing patterns and costs among hospital inpatients with chronic kidney
disease (CKD) not on dialysis.METHODS: Electronic records from the Premier Hos-
pital Database (2006Q1-2011Q1) were used to identify inpatients that had a diag-
nosis for CKD and had received epoetin alfa (EPO) or darbepoetin alfa (DARB).
Exclusion criteria were:18 years, receipt of renal dialysis, a diagnosis of cancer or
myelodysplastic syndrome, receipt of chemotherapy, or receipt of both ESAs. The
observation period consisted of the hospital inpatient stay. The dose only ratio
(Units EPO: mcg DARB) was calculated using the mean cumulative dose of EPO and
DARB. Treatment costs for both ESA groups were determined using cumulative
dose and published July 2011 wholesale acquisition costs. RESULTS: A total of
135,432 inpatient stays (EPO: 104,195; DARB: 31,237) were identified. The EPO group
was slightly younger than the DARB group (69.5 vs. 70.0 years, respectively;
P0.001), and had a higher proportion of females (52.1% vs. 51.2%, respectively;
P0.022). Length of stay (LOS) was similar withmean LOS of EPO9.3 vs. DARB9.2
days, (P0.084). The mean cumulative dose was EPO 35,355 Units and DARB 128
mcg, which resulted in a dose only ratio (Units EPO: mcg DARB) of 276:1. Corre-
sponding mean ESA treatment costs were higher for DARB than for EPO (EPO: $573
vs. DARB: $718; P0.001). CONCLUSIONS: In this analysis of non-dialysis CKD in-
patient records, a dose only ratio (Units EPO: mcg DARB) of 276:1 was observed.
Mean ESA treatment costswere found to be approximately 25%higher for theDARB
group versus EPO group despite similar length of stay between the groups.
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OBJECTIVES: To understand the trends in rate and cost of hospitalizations due to
Chronic Kidney Disease (CKD) in the United States. METHODS: We analyzed last
five years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage
Renal Disease (ESRD). The annual number of hospitalizations for specific diagnosis
were obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-
2009. Data were also analyzed for length of stay (LOS), charges and cost of
hospitalization. RESULTS: During last five years the number of hospitalizations
with diagnosis of CKD and ESRD have increased 4.1 and 4.6 fold, respectively. In
2009, an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of
CKD and ESRD, respectively. The mean LOS for patients with CKD has increased
from 4.9 to 5.5 days, during 2005-2009. The mean LOS for patients with ESRD has
remained steady at 6 days during 2005-2009. The cost of hospitalization with
diagnosis of CKD has increased 31% during 2005-2009. The cost of hospitalization
with diagnosis of ESRD has increased 21% during 2005-2009. In 2009, themean cost
of hospitalization for patients with CKD and ESRD were $11,209 and $21,358,
respectively. CONCLUSIONS: Hospitalizations due to CKD and ESRD have signifi-
cantly increased during last five years. There is a need for prevention, treatment
and disease management programs to lower the medical and socioeconomic bur-
den of this disease.
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OBJECTIVES: To evaluate the cost of anemia management according to hemoglo-
bin level variability in hemodialysis (HD) patients.METHODS:Thiswas a retrospec-
tive study based on computerized medical files, (Hemodial® software database),
which included 636 HD patients in 5 dialysis centers in 2009. Patients were evalu-
able if they were regularly hemodialyzed, had at least one Hb recorded per month
and were monitored for at least 4 months. “Annual Hb values” were categorized
according to theirmonthlymeanHb (Ideal [10Hb 12 g/dL; n119]; High [Hb12
g/dL; n61] and Low [Hb  10 g/dL; n18] if 75% of time in respective category,
otherwise categorized in Fluctuating; n438). RESULTS: Out of 636 evaluable pa-
tients (mean age, 67 y; male, 59.4%) underwent 144 HD sessions (median); 16.8%
were new dialysis patients. The cost of anemiamanagement wasmainly related to
erythropoiesis-stimulating agents (68% of total cost for Low category and approx-
imately 90% for other categories). Adjusted predictive factors for higher costs of
anemia management (p0.0001) were: dialysis center (from 2518 to 5617€), age
(4911€  55 y vs. 5378€ 65–75 y), female gender (4911€ vs. 4398€ for male), serum
ferritin (5102€ for 200–500 g/mL vs. 4646€ for 500 g/mL) and dialysis vintage
(4911€ if  2 y vs. 2952€ if 4–6 y). The cost for patients in the Low Hb category (13
005€) was significantly higher compared to the others categories: Ideal (5034€),
Fluctuating (4911€) and High (2418€). CONCLUSIONS: Predictive of higher costs of
anemiamanagement in HD patients were the dialysis center, Low Hb category and
patients starting dialysis. Different treatment strategies led to acceptable Hb levels
but showed substantially different costs.
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OBJECTIVES: According to 2009 figures from the US Renal Data System, 17% of all
patients received their first dialysis with private insurance coverage. Ferric citrate
(FC) is a phosphate binder (PB) in clinical development for the treatment of hyper-
phosphatemia in ESRD patients. Patients receiving FC in clinical studies experi-
enced reductions in serum phosphorus, and increases in serum ferritin and satu-
rated transferrin (TSAT). In an observational study analyzing data of a large dialysis
provider, similar increases in ferritin and TSAT in patients with stable hemoglobin
were associated with reduced doses of intravenous (IV) iron and erythropoiesis-
stimulating agents (ESAs) such as epoetin alfa. Reduced IV iron and ESA use could
lower costs of ESRD treatment for insurers.METHODS:We created amanaged care
cost-offset model that considered annual treatment costs of ESRD patients pre-
scribed FC versus alternative PBs. The model assumed similar efficacy and cost
neutrality between FC and other PBs. Baseline input values were derived from
published sources as well as a database analysis from a large US dialysis provider.
Monte Carlo simulations were performed using varying model inputs such as the
number of patients insured, proportion of ESRD patients on PBs, number of dialysis
sessions, estimated cost for dialysis, and ESA and iron costs from observed dose
ranges. RESULTS: Results of the simulation were used to derive a 90% confidence
interval for the potential annual cost savings realized with FC use. Simulations
show a 90% probability that an insurer serving 500 dialysis patients could save
between $389,000 and $829,000 annually with the use of FC. The model was most
sensitive to the number of dialysis sessions per month, health plan size, ESA cost,
and proportion of ESRD patients receiving PBs. CONCLUSIONS: The use of FC over
alternative PBs could create a meaningful cost-offset savings and help reduce the
economic burden of treating patients with ESRD.
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OBJECTIVES: The United States Renal Data System reported that of $2.78 billion
spent on injectable drugs for patients with end-stage renal disease (ESRD) during
2009, $1.89 billion was for erythropoiesis-stimulating agents (ESAs), such as epo-
etin alfa. These costs were reimbursed to dialysis providers under the Medicare
Prospective Payment System, where dialysis payment is bundled with injectable
drugs payment. Oral ferric citrate (FC) is a phosphate binder in clinical develop-
ment for hyperphosphatemia treatment in ESRD patients. Clinical trials demon-
strated that FC lowers patients’ serum phosphorus levels with the added benefit of
increasing patients’ serum ferritin and saturated transferrin (TSAT) levels. In an
observational study analyzing data of a large dialysis provider, similar increases in
ferritin and TSAT in patientswith stable hemoglobinwere associatedwith reduced
doses of intravenous (IV) iron and ESAs. METHODS: We created a facility-level
Medicare cost-offset model that considered annual costs of ESRD treatment for
patients prescribed FC versus other phosphate binder medications (PBs). The
model assumed equal price and efficacy between FC and competitor PBs. Model
inputs included the Medicare average sales price of iron and ESAs, proportion of
ESRD patients on PBs, facility-level cost, and Medicare reimbursement rates with
case-mix adjusters. Margin was calculated as the difference between reimburse-
ment and cost.We assessed the effects of FC use to dialysis providers by comparing
margin for patients on FC versus those taking other PBs. RESULTS: With FC use
versus other PBs, annual facility-level reductions in ESA and IV iron administration
were 9.60% and 11.9%, respectively. These decreases translated to an annual cost
savings of approximately 2.56% of the facility’s total annual bundled Medicare
reimbursement. CONCLUSIONS: A 2% potential cost savings with FC use in pa-
tients taking PBs would be an important opportunity for dialysis providers to re-
duce patients’ treatment costs under Medicare’s Prospective Payment System.
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OBJECTIVES: DKD is the primary cause of ESRD in the US, with 45% of ESRD
associated with diabetes. A cost-effectiveness model was created to evaluate the
long-term costs and benefits of a therapeutic intervention that slows the progress
to ESRD in DKD patients.METHODS: The model is a Monte Carlo microsimulation
of a semi-Markov structure with a lifetime patient perspective. Kidney disease is
modeled as normal, Stages 1 through 5, and ESRD. Proteinuria is modeled as none,
microalbuminuria, andmacroalbuminuria. Themodel incorporates cardiovascular
disease (CVD) events and mortality along with non-CVD mortality. Modeled costs
are therapy costs, regression-equation supplied annual medical costs, and ESRD
costs. Analyses were performed for diabetic males receiving ACEi or ARB therapy,
age 60, macroalbuminuria, and estimated glomerular filtration rates (eGFR) of 30
(Stage 3/4 breakpoint) and 40 (Stage 3b) mL/min/1.73m2. The intervention was
modeled as a chronic pharmaceutical therapy to be administered through kidney
disease Stage 4. We assume this confers a 28% reduction in annual eGFR degrada-
tion; this is in addition to the base case ARB-attributed reduction in eGFR degrada-
tion. Separate economic analyses were performed for annual intervention costs of
$2500 and $7500. RESULTS: Compared with SOC (i.e., ACEi or ARB treatment), and
respectively in patients at eGFRs of 30 and 40, the intervention increased QALYs
(0.29, 0.51) and life years (0.30, 0.66) and also resulted in fewer patients
reaching ESRD (-74/1,000; -104/1,000). For the intervention cost of $2500, cost sav-
ings were realized for both eGFR cohorts. For the $7,500 cost, cost-per-QALY ICERs
were calculated to be $79,965 for the eGFR 30 and $75,052 for the eGFR 40 cohorts.
CONCLUSIONS: Use of an effective therapeutic intervention to slow progression to
ESRD in high risk DKD patients can result in medical benefits (i.e., ESRD cases
avoided) and can be cost-effective or even cost saving.
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OBJECTIVES: To determine the cost-effectiveness of pharmacologic treatments for
overactive bladder.METHODS:A decisionmodel was constructed based on studies
of effectiveness, adverse consequences, comorbid conditions, and medical costs
for the treatment of overactive bladder. The model was based on a previously
published cost-effectiveness model. The 3 month model classifies patients to 1 of
three states after treatments including: 1) complete continence; 2) treatment fail-
ure; and 3) discontinuation of treatment. Estimates of complete continence were
obtained from trials involving products on the US market as of February 2011.
These products included darifenacin, fesoterodine, oxybutynin immediate release
(IR), oxybutynin extended release (ER), oxybutynin topical gel, oxybutynin trans-
dermal patch, solifenacin, tolterodine IR, tolterodine ER, trospium IR, and trospium
ER. A systematic search of MEDLINE and Embase was conducted to identify rele-
vant studies. Costs were derived from the literature and updated to 2011 values
using themedical components of the consumer price index. Medication costs were
based on wholesale acquisition cost. Probabilistic sensitivity analysis was con-
ducted using a Monte Carlo simulation. RESULTS: A total of 51 studies were iden-
tified, of which 11 studies reported complete continence rates. Complete conti-
nence rates ranged from 19.0% for darifenacin to 51.0% for solifenacin. The lowest
cost treatment was oxybutynin IR ($752 per patient) and the highest cost was
trospium IR ($1,223 per patient). The product with the lowest ICER relative to oxy-
butynin was solifenacin at $1,405 per additional continent patient. The cost-effec-
tiveness acceptability curve indicated oxybutynin IR was most cost-effective with
willingness-to-pay (WTP) values less than $10,000, and solifenacin was most cost-
effective at higher WTP values. CONCLUSIONS: Compared with generic oxybu-
tynin IR, only solifenacinwasmore cost-effective and had an ICER below $1,500 per
successfully treated patient. Only oxybutynin IR and solifenacin had a non-zero
probability of being cost-effective as compared to other therapies.
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OBJECTIVES: Pharmacists successfully manage patients with anemia and chronic
kidney disease (CKD), but these programs’ cost-effectiveness is unknown. This
analysis examines the cost-effectiveness of pharmacist-managed erythropoiesis-
stimulating agents (ESAs) clinics compared to usual physician-based care in pa-
tients with non-dialysis (ND) CKD. METHODS: A Markov model estimated the in-
cremental cost-effectiveness of pharmacist-managed ESA clinics compared with
usual care in outpatients receiving ESAs for ND-CKD at ten VA Medical Centers
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